-
Professor Jasmohan Bajaj talks about the overuse and misuse of antibiotics and how this will cause an international pandemic, if the "reset-button" to deescalate the use of antibiotics is not pressed soon.
-
Professor Subrata Ghosh summarises the key findings of the ICONIC-study, which is the largest ongoing observational study on the burden of adult ulcerative colitis in patients under routine care. It comprises 1.816 enrolled patients in 33 countries throughout the globe.
-
Crohn’s disease (CD) is a progressive disorder and the achievement of mucosal healing lowers the risk of necessary surgery, according to Julián Panés (Spain).
-
As early as week 2, patient-reported symptomatic improvements were achieved among UC patients treated with vedolizumab – including a combined reduction in defecation frequency and rectal blood loss. These findings underline the fast action of vedolizumab in treating UC, particularly when it is used as a first-line biological therapy.
-
During the word of welcome given at the satellite symposium 'Rapid Action and Lasting Remission - Focus on Disease Progression in Ulcerative Colitis', William Sandborn came directly to the point: the sufficient treatment of UC is essential. In 50% of the patients suffering from the UC, the disease takes an adverse course.
-
A bridging strategy in which a calcineurin inhibitor and vedolizumab are combined seems to be effective in patients with active steroid-refractory ulcerative colitis. Such a strategy could be considered for patients with acute, severe UC and nonsevere UC that are resistant to conventional therapy, including anti-tumour necrosis factor (anti-TNF).
-
Professor Pierre Michetti summarizes new approaches in the treatment of ulcerative colitis.
-
In our interview, Professor Janindra Warusavitarne talks about minimally invasive surgical intervention for patients with severe ulcerative colitis.
-
Professor Chris Probert talks about the current state of research and presents results of a recent study on clinical efficacy and patient safety of Golimumanb for induction and maintenance in patients with moderate to severe colitis ulcerosa.
-
Dr. Peter Bossuyt summarizes his scientific talk about results of the Real Life - BE SMART study. He primarily speaks about an early mucosal healing in connection with the TNF-α inhibitor Golimumab.
-
From biologicals to microbiome: Dr. Johan Burisch informs about the most exciting developments in research and treatment of chronic inflammatory bowel disease (IBD).
